16 December 2021

ViCentra closes EUR 65M (USD 74M) Series C funding to expand the footprint of Kaleido across Europe

  • New investor, Partners in Equity – joins existing investors Health Innovations, INKEF Capital LSP and Invest-NL
  • Proceeds will be used for commercial European launch of updated Kaleido insulin patch pump system including automated insulin delivery (AID) or closed loop

December 16, 2021, Utrecht, The Netherlands – ViCentra, the company behind Kaleido, the world’s smallest and lightest wearable insulin pump (“patch pump”), announces the closing of a EUR 65 million (USD 74 million) Series C financing. The investment round was led by new investor Partners in Equity BV, the Amsterdam based Venture Capital firm with a long-term focus. Existing investors LSP, INKEF Capital and Health Innovations also participated in the investment.

Frans Cromme, CEO of ViCentra commented: “This new equity round enables us to further accelerate our commercial rollout, scale our manufacturing operations and prepare for FDA filing. The commercial launch of the Kaleido system will focus on the Netherlands, France, Germany and the UK, with additional regions targeted in due course.”

In addition, the company announces it has commercially launched the next generation of its Kaleido system which fits the DBLG1 System, Diabeloop’s advanced closed loop automated insulin delivery (“AID”) solution. By further strengthening its collaboration with Diabeloop, Kaleido will be available to operate with the DBLG1 handset and proprietary algorithm. This will bring the AID system with a wearable pump to Europe, with the advanced dosing algorithm and intuitive user interface developed by Diabeloop.

Frans Cromme added: “We are excited to be further expanding our product offering with a closed loop system and to be introducing this product to new EU markets. The system is simple and easy to use, bringing a significant improvement in quality of life to people with type 1 diabetes. This is in line with ViCentra’s philosophy to design brilliantly engineered healthcare products that truly put people first. We don’t design for patients – we design for people.”

The World Health Organization estimates that there are about 422 million people with diabetes across the globe, with numbers expected to grow as the global population ages. As both people with type 1 diabetes and providers rely more and more on virtual care, this provides a tremendous opportunity for technology to help improve the quality of life for people with type 1 diabetes.

Contact for media enquiries:

Optimum Strategic Communications

Supriya Mathur, Charlotte Hepburne-Scott

Tel: +44 (0)20 3882 9621

Email: ViCentra@optimumcomms.com

About ViCentra

ViCentra B.V., with headquarters in Utrecht, the Netherlands develops, manufactures and markets next generation insulin pumps and other products to treat people with diabetes. The company’s flagship product is the Kaleido insulin pump which is CE marked and commercially released in certain European countries. ViCentra was founded in 2013 and is backed by Health Innovations, INKEF Capital, LSP, Invest-NL, Partners in Equity BV and Kreos Capital. The highly experienced team has expertise in scaling manufacturing, commercialisation and regulatory filing. More information about ViCentra can be found at www.hellokaleido.com.

About Partners in Equity BV

Partners in Equity is an Amsterdam based privately owned investment firm established in 2003. Partners in Equity partner with those who push boundaries, have a holistic view and seek to fulfil one or more United Nations Sustainable Development Goals (SDGs). Partners in Equity focus on tech investment opportunities in Agrifood, Education and Healthcare. For more information www.pi-equity.com